Background and aims: The current systematic review aimed to elucidate the effects of lipid variability on microvascular complication risk in diabetic patients. The lipid components studied were as follows: LDL, HDL, TG, Total Cholesterol, and Remnant Cholesterol. Method: We carried out a systematic search in multiple databases, including PubMed, Google Scholar, and Scopus, up to September 2022. Finally, after omitting the duplicates, 2724 studies were left, 104 related articles were extracted from the databases, and five articles were included in the study after screening the title, abstract and full text. Result: Five studies (4 cohorts and one cross-sectional) with a total population of 138664 were reviewed. These studies were done in China, Japan, Hong Kong, Taiwan, and Italy. The average age of the patients varied from 45 to 84 years. The follow-up duration of cohort studies ranged from 4 to 7 years. These studies have shown that higher LDL, HDL, and TG variability adversely affect microvascular complications, especially nephropathy and neuropathic complications. TG and LDL variability was associated with developing albuminuria and GFR decline. In another study, a lower HDL variation had a protective effect on microalbuminuria. In contrast, another study has shown no evidence of a relationship between lipid variation and microvascular complications such as retinopathy. Conclusion: The relationship between lipid variation (LDL, HDL, and TG) (adverse effects) on microvascular complications, especially nephropathy and neuropathic (and maybe not retinopathy), is proven. Physicians and health policymakers should be highly vigilant to lipid variation in a general population.

Background and aims: Venous thromboembolism (VTE) is a common complication of malignancy associated with a three-fold increase risk of death. Pregnancy is also a recognized risk factor for VTE, and is associated with a 4-5 fold increase risk compared to non-pregnant women. Considering that any review article has not been published in this field yet and given that complications of VTE can be reduced by early identifying between pregnant women the current systematic review aimed to elucidate the impact of malignancy on the risk of VTE in pregnant females. Methods: We carried out a systematic search in multiple databases, including PubMed (Medline), Google Scholar, and Scopus up to January 2023. Finally, 441 related articles were extracted from the databases, after screening the title, abstract and full text, seven articles were included in the study. Results: Seven studies (6 cohorts and 1 cross-sectional) with an entire of 58,854,195 pregnant females (22,396 cancer patients) were included. These studies were done in the United States of America, Canada, Brazil, and Denmark. All of the studies except one study demonstrated that cancer in pregnant patients increased the risk of deep vein thrombosis (DVT). The VTE prevalence was significantly higher in cancer groups compared with the non-cancer group and the highest (adjusted odds ratio) aOR was correlated to myeloid leukemia. Conclusions: Pregnant women with malignancy are more susceptible to VTE and other coagulation disorders. Physicians and health policymakers should be of high vigilance to pregnancy-associated VTE, especially in women suffering from cancer.